Rating to Follow: Does Munich Re (MURGY) Look Bad? Kepler Downgrades It

November 29, 2016 - By Marguerite Chambers

Rating to Follow: Does Munich Re (MURGY) Look Bad? Kepler Downgrades It

Munich Re (MURGY) Downgrade

Munich Re (MURGY) was downgraded by Kepler from a “Hold” rating to a “Reduce” rating in a a report issued to clients on Tuesday, 29 November.

About 35,772 shares traded hands. Muenchener Rueckversicherungs-Ges.AG-ADR (MURGY) has declined 6.50% since April 26, 2016 and is downtrending. It has underperformed by 11.76% the S&P500.

Analysts await Muenchener Rueckversicherungs-Ges.AG-ADR (OTCMKTS:MURGY) to report earnings on March, 15.

Muenchener Rueckversicherungs Gesellschaft in Muenchen AG is a Germany firm engaged in reinsurance and insurance business. The company has a market cap of $29.44 billion. The Firm divides its activities into reinsurance, primary insurance, and Munich Health and Asset management. It currently has negative earnings. The Reinsurance business comprises five divisions: Life; Europe and Latin America; Germany, Asia Pacific and Africa; Special and Financial Risks, and Global Clients and North America.

According to Zacks Investment Research, “Münchener Rückversicherungs-Gesellschaft is engaged in the insurance and reinsurance businesses worldwide. The segments that form the basis of its integrated business model are Reinsurance, Primary insurance and Munich Health. The company’s reinsurance products include casualty reinsurance, property reinsurance, marine reinsurance and special lines reinsurance along with life and health reinsurance. Its primary insurance segment offers its clients a broad range of products of insurances for private, commercial and industrial needs. The Company provides life and property insurance along with health insurance, legal expenses insurance and travel insurance. Munich Health brand combines its global healthcare knowledge in primary insurance and reinsurance. Münchener Rückversicherungs-Gesellschaft is headquartered in Munich, Germany.”

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News